GENCEPT 10/11-28
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GENCEPT 10/11-28 (GENCEPT 10/11-28).
Combination of ethinyl estradiol (estrogen) and levonorgestrel (progestin) inhibits ovulation by suppressing gonadotropin release, increases cervical mucus viscosity to impede sperm penetration, and alters endometrial receptivity.
| Metabolism | Ethinyl estradiol: primarily CYP3A4; Levonorgestrel: CYP3A4, undergoes reduction and sulfation. |
| Excretion | Renal excretion accounts for approximately 70% of elimination (as unchanged drug and metabolites), with about 10% biliary/fecal. The remaining is metabolized. |
| Half-life | Terminal elimination half-life is approximately 8-12 hours. Steady state is achieved within 2-3 days. |
| Protein binding | 98% bound to serum proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is approximately 0.8-1.0 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability is approximately 90%, with minimal first-pass metabolism. |
| Onset of Action | Oral administration: 2-3 hours for plasma concentration to reach therapeutic levels. |
| Duration of Action | Duration is approximately 24 hours due to once-daily dosing, with sustained plasma levels throughout the day. |
One tablet (ethinyl estradiol 0.01 mg/levonorgestrel 0.1 mg) orally once daily for 28 days. For the first 21 days, active tablets are taken; the next 7 days are placebo tablets.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. In severe renal impairment (GFR <30 mL/min), use with caution due to potential fluid retention and hypertension. |
| Liver impairment | Contraindicated in patients with Child-Pugh class B or C hepatic impairment (moderate to severe). In mild hepatic impairment (Child-Pugh class A), use with caution due to altered hormone metabolism. |
| Pediatric use | Not indicated for use in pediatric patients before menarche. For post-menarche adolescents, follow same dosing as adults. |
| Geriatric use | Not indicated for use in women above 55 years of age due to increased risk of thromboembolic events and lack of efficacy data. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for GENCEPT 10/11-28 (GENCEPT 10/11-28).
| Breastfeeding | Gestodene and ethinylestradiol are excreted in breast milk in small amounts. The M/P ratio for ethinylestradiol is approximately 0.02; for gestodene, it is unknown but likely low. Combined hormonal contraceptives may reduce milk production and composition, especially in early lactation; use is generally not recommended during breastfeeding, particularly in the first 6 months postpartum. Progestin-only alternatives are preferred. |
| Teratogenic Risk | GENCEPT 10/11-28 contains gestodene and ethinylestradiol. Gestodene is a progestogen; ethinylestradiol is an estrogen. Combined hormonal contraceptives are contraindicated in pregnancy. First trimester: no increased risk of major birth defects based on epidemiological studies, but should not be used once pregnancy is confirmed. Second and third trimesters: no therapeutic indication; animal studies show fetotoxicity at high doses. Overall, use is not recommended in pregnancy. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Women over 35 who smoke should not use this product.
| Serious Effects |
["Thrombophlebitis or thromboembolic disorders","Cerebrovascular or coronary artery disease","Known or suspected breast cancer","Estrogen-dependent neoplasia","Undiagnosed abnormal genital bleeding","Cholestatic jaundice of pregnancy or jaundice with prior pill use","Hepatic adenoma or carcinoma","Known or suspected pregnancy","Hypersensitivity to any component"]
| Precautions | ["Thrombotic disorders (thrombophlebitis, pulmonary embolism, stroke, MI)","Visual abnormalities (retinal thrombosis, papilledema)","Hepatic neoplasia (benign/malignant liver tumors)","Hypertension","Glucose intolerance/diabetes","Gallbladder disease","Depression","Bleeding irregularities"] |
Loading safety data…
| Fetal Monitoring | Not applicable during pregnancy as drug is contraindicated. If inadvertent exposure occurs, no specific fetal monitoring is required beyond routine prenatal care. For postpartum use while breastfeeding, monitor infant for jaundice, weight gain, and developmental milestones; no routine maternal monitoring beyond standard contraceptive surveillance. |
| Fertility Effects | GENCEPT 10/11-28 is a combined oral contraceptive; it works by inhibiting ovulation and altering cervical mucus. Fertility returns promptly after discontinuation, typically within 1-2 cycles. No evidence of permanent fertility impairment. Long-term use does not affect future fertility or increase risk of infertility. |